231 research outputs found
B833: A Residential Waste Stream Analysis: Orono, Maine, 1990
George Criner and Chet Rock of the University of Maine, and students from their Waste Management class analyzed household wastes from 33 residences in Orono. The purpose of the analysis was to obtain an estimate of total weekly residential waste weight and its composition by category (paper versus glass, etc.).https://digitalcommons.library.umaine.edu/aes_bulletin/1022/thumbnail.jp
B812: Dairy Farmer Indebtedness in Maine
The dairy industry in Maine is an important contributor to the agricultural sector and general economy. In 1982 there were 750 employees processing dairy products in Maine drawing a 12 million dollar payroll (Maine Bureau of Labor). The 1983 farm-gate value of milk produced in Maine totaled 108 million dollars, higher than any other single commodity\u27s farm-gate value (Maine Department of Agriculture, Food and Rural Resources). For the past several years the farm level price of milk has remained fairly steady while production costs inflated. This price-cost squeeze worsened in 1983 with a 50 cent per hundredweight decrease in the price received by farmers which was authorized by the Dairy and Tobacco Adjustment Act of 1983.
Limited public information is available concerning the financial health of Maine\u27s dairy farming sector. This aspect is of crucial concern to policy makers in the state. Toward this end the Maine Dairy Industry Association requested that the University of Maine at Orono, in cooperation with the Maine Department of Agriculture, Food and Rural Resources, conduct a study to provide an accurate overall picture of the financial structure and business management practices of Maine\u27s dairy farms.https://digitalcommons.library.umaine.edu/aes_bulletin/1111/thumbnail.jp
TB204: Organic Milk Production in Maine: Attributes, Costs, and Returns
This report summarizes attributes, costs, and returns for organic dairy farms in Maine that responded to the 2008 dairy cost of production survey. This survey and analysis was conducted by the University of Maine in cooperation with the Maine Milk Commission. This publication reports on data collected over the 2007 production year. Analysis and discussion of the data revolve around four categories. The first category averages all 30 organic farms to create a statewide group. The authors then broke these 30 farms into three size groups (small, medium, and large) based on the number of cows on each farm. There were nine small farms with an average of 30 cows on each farm, 10 medium farms with an average of 55 cows each, and 11 large farms with about an average of 100 cows each. The analysis presented here discusses characteristics of the three size groups, along with the statewide group.https://digitalcommons.library.umaine.edu/aes_techbulletin/1009/thumbnail.jp
Recommended from our members
Relationship between diffusion capacity and small airway abnormality in COPDGene.
Impaired single breath carbon monoxide diffusing capacity (DLCO) is associated with emphysema. Small airways disease (SAD) may be a precursor lesion to emphysema, but the relationship between SAD and DLCO is undescribed. We hypothesized that in mild COPD, functional SAD (fSAD) defined by computed tomography (CT) and Parametric Response Mapping methodology would correlate with impaired DLCO. Using data from ever-smokers in the COPDGene cohort, we established that fSAD correlated significantly with lower DLCO among both non-obstructed and GOLD 1-2 subjects. The relationship between DLCO with CT-defined emphysema was present in all GOLD stages, but most prominent in severe disease. TRIAL REGISTRATION: NCT00608764. Registry: COPDGene. Registered 06 February 2008, retrospectively registered
Four patients with a history of acute exacerbations of COPD: implementing the CHEST/Canadian Thoracic Society guidelines for preventing exacerbations
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0
Recommended from our members
Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.
ObjectiveBronchodilator responsiveness (BDR) is prevalent in COPD, but its clinical implications remain unclear. We explored the significance of BDR, defined by post-bronchodilator change in FEV1 (BDRFEV1) as a measure reflecting the change in flow and in FVC (BDRFVC) reflecting the change in volume.MethodsWe analyzed 2974 participants from a multicenter observational study designed to identify varying COPD phenotypes (SPIROMICS). We evaluated the association of BDR with baseline clinical characteristics, rate of prospective exacerbations and mortality using negative binomial regression and Cox proportional hazards models.ResultsA majority of COPD participants exhibited BDR (52.7%). BDRFEV1 occurred more often in earlier stages of COPD, while BDRFVC occurred more frequently in more advanced disease. When defined by increases in either FEV1 or FVC, BDR was associated with a self-reported history of asthma, but not with blood eosinophil counts. BDRFVC was more prevalent in subjects with greater emphysema and small airway disease on CT. In a univariate analysis, BDRFVC was associated with increased exacerbations and mortality, although no significance was found in a model adjusted for post-bronchodilator FEV1.ConclusionWith advanced airflow obstruction in COPD, BDRFVC is more prevalent in comparison to BDRFEV1 and correlates with the extent of emphysema and degree of small airway disease. Since these associations appear to be related to the impairment of FEV1, BDRFVC itself does not define a distinct phenotype nor can it be more predictive of outcomes, but it can offer additional insights into the pathophysiologic mechanism in advanced COPD.Clinical trials registrationClinicalTrials.gov: NCT01969344T4
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD:results on cardiovascular safety from the IMPACT trial
BACKGROUND: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy. METHODS: IMPACT was a 52-week, randomized, double-blind, multicenter Phase III study comparing the efficacy and safety of FF/UMEC/VI 100/62.5/25 mcg with FF/VI 100/25 mcg or UMEC/VI 62.5/25 mcg in patients ≥40 years of age with symptomatic chronic obstructive pulmonary disease (COPD) and ≥1 moderate/severe exacerbation in the previous year. The inclusion criteria for the study were intentionally designed to permit the enrollment of patients with significant concurrent CV disease/risk. CV safety assessments included proportion of patients with and exposure-adjusted rates of on-treatment CV adverse events of special interest (CVAESI) and major adverse cardiac events (MACE), as well as time-to-first (TTF) CVAESI, and TTF CVAESI resulting in hospitalization/prolonged hospitalization or death. RESULTS: Baseline CV risk factors were similar across treatment groups. Overall, 68% of patients (n = 7012) had ≥1 CV risk factor and 40% (n = 4127) had ≥2. At baseline, 29% of patients reported a current/past cardiac disorder and 58% reported a current/past vascular disorder. The proportion of patients with on-treatment CVAESI was 11% for both FF/UMEC/VI and UMEC/VI, and 10% for FF/VI. There was no statistical difference for FF/UMEC/VI versus FF/VI or UMEC/VI in TTF CVAESI (hazard ratio [HR]: 0.98, 95% confidence interval [CI]: 0.85, 1.11; p = 0.711 and HR: 0.92, 95% CI: 0.78, 1.08; p = 0.317, respectively) nor TTF CVAESI leading to hospitalization/prolonged hospitalization or death (HR: 1.19, 95% CI: 0.93, 1.51; p = 0.167 and HR: 0.96, 95% CI: 0.72, 1.27; p = 0.760, respectively). On-treatment MACE occurred in ≤3% of patients across treatment groups, with similar prevalence and rates between treatments. CONCLUSIONS: In a symptomatic COPD population with a history of exacerbations and a high rate of CV disease/risk, the proportion of patients with CVAESI and MACE was 10-11% and 1-3%, respectively, across treatment arms, and the risk of CVAESI was low and similar across treatment arms. There was no statistically significant increased CV risk associated with the use of FF/UMEC/VI versus FF/VI or UMEC/VI, and UMEC/VI versus FF/VI. TRIAL REGISTRATION: NCT02164513 (GSK study number CTT116855)
InforMing the PAthway of COPD Treatment (IMPACT) Trial: Fibrinogen Levels Predict Risk of Moderate or Severe Exacerbations
Background: Fibrinogen is the frst qualifed prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated futicasone furoate/umeclidinium/ vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients with symptomatic COPD at risk of exacer‑ bations. This analysis used IMPACT trial data to examine the relationship between fbrinogen levels and exacerbation outcomes in patients with COPD.
Methods: 8094 patients with a fbrinogen assessment at Week 16 were included, baseline fbrinogen data were not measured. Post hoc analyses were performed by fbrinogen quartiles and by 3.5 g/L threshold. Endpoints included on-treatment exacerbations and adverse events of special interest (AESIs).
Results: Rates of moderate, moderate/severe, and severe exacerbations were higher in the highest versus lowest fibrinogen quartile (0.75, 0.92 and 0.15 vs 0.67, 0.79 and 0.10, respectively). The rate ratios (95% confidence interval [CI]) for exacerbations in patients with fibrinogen levels ≥ 3.5 g/L versus those with fibrinogen levels \u3c 3.5 g/L were 1.03 (0.95, 1.11) for moderate exacerbations, 1.08 (1.00, 1.15) for moderate/severe exacerbations, and 1.30 (1.10, 1.54) for severe exacerbations. There was an increased risk of moderate/severe exacerbation (hazard ratio [95% CI]: highest vs lowest quartile 1.16 [1.04, 1.228]; ≥ 3.5 g/L vs \u3c 3.5 g/L: 1.09 [1.00, 1.16]) and severe exacerbation (1.35 [1.09, 1.69]; 1.27 [1.08, 1.47], respectively) with increasing fibrinogen level. Cardiovascular AESIs were highest in patients in the highest fibrinogen quartile.
Conclusions: Rate and risk of exacerbations was higher in patients with higher fbrinogen levels. This supports the validity of fbrinogen as a predictive biomarker for COPD exacerbations, and highlights the potential use of fbrinogen as an enrichment strategy in trials examining exacerbation outcomes
Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study
Background: Anxiety in patients with chronic obstructive pulmonary disease (COPD) is associated with selfreported
disability. The purpose of this study is to determine whether there is an association between anxiety and
functional measures, quality of life and dyspnea.
Methods: Data from 1828 patients with moderate to severe emphysema enrolled in the National Emphysema
Treatment Trial (NETT), collected prior to rehabilitation and randomization, were used in linear regression models to
test the association between anxiety symptoms, measured by the Spielberger State Trait Anxiety Inventory (STAI)
and: (a) six-minute walk distance test (6 MWD), (b) cycle ergometry peak workload, (c) St. Georges Respiratory
Questionnaire (SRGQ), and (d) UCSD Shortness of Breath Questionnaire (SOBQ), after controlling for potential
confounders including age, gender, FEV1 (% predicted), DLCO (% predicted), and the Beck Depression Inventory
(BDI).
Results: Anxiety was significantly associated with worse functional capacity [6 MWD (B = -0.944, p < .001),
ergometry peak workload (B = -.087, p = .04)], quality of life (B = .172, p < .001) and shortness of breath (B = .180,
p < .001). Regression coefficients show that a 10 point increase in anxiety score is associated with a mean decrease
in 6 MWD of 9 meters, a 1 Watt decrease in peak exercise workload, and an increase of almost 2 points on both
the SGRQ and SOBQ.
Conclusion: In clinically stable patients with moderate to severe emphysema, anxiety is associated with worse
exercise performance, quality of life and shortness of breath, after accounting for the influence of demographic
and physiologic factors known to affect these outcomes.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91944/1/2010 RR Anxiety is associated with diminished exercise performance and quality of life in severe emphysema.pd
- …